CTAD Asia-China thanks privileged partners for their continued support:

2019 - GOLD SPONSORS

![Eisai](image1)
![Green Valley](image2)
![Roche](image3)

2019 - SILVER SPONSORS

![APRINOIA](image4)
![Quanterix](image5)
![IXICO](image6)
![Neoline](image7)
![Lundbeck](image8)
![Innovative](image9)
![Cerecin](image10)
![Magou](image11)
SUMMARY

Organizing & Scientific Committees 4
Preliminary program 6
Friday, October 11 6
Saturday, October 12 8
Posters 11
Congress venue 14

CTAD 2019
Beijing
CTAD Organizing Committee

Jacques Touchon, (French Academician) MD, PhD Professor or Neurology Montpellier University Hospital, INSERM U1061, Honorary Dean of the Montpellier School of Medicine, Montpellier, France

Jeffrey L. Cummings, MD, Sc.D. Camille and Larry Ruvo Chair for Brain Health Director, Cleveland Clinic Lou Ruvo Center for Brain Health Director, Center for Neurodegeneration and Translational Neuroscience Professor, Cleveland Clinic Lerner College of Medicine Las Vegas, Nevada - USA

Bruno Vellas, (French Academician) MD, PhD chair of the Gerontopole & Department of Geriatric Internal Medicine at the Toulouse University Hospital Member of the INSERM UMR 1027, adjunct professor at the Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA, Chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training since September 2017

Piu Chan, MD, PhD Professor and Director, Beijing Institute of Geriatrics, Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Disorders, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China

Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Disorders, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China

Serge Gauthier, C.M., C.Q., MD, FRCP Professor in the Departments of Neurology & Neurosurgery, Psychiatry, Medicine, at McGill University, and Director of the Alzheimer Disease and Related Disorders Research Unit of the McGill Center for Studies in Aging, Douglas Hospital, Montréal, Canada

Paul Aisen, MD Alzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego

Yong Shen, PhD, Distinguished Professor of Neuroscience and Neurology Director Neurodegenerative Disorder Research Center, University of Science and Technology of China, Member, Hefei Matral Science National Laboratory at Microscale, Member, Excellent Center for Brain Sciences and Artificial Intelligence in China Academy of Sciences, Hefei, China

CTAD Scientific Committee (in alphabetical order)

Hidenori Arai, MD, PhD Deputy Director, National Center for Geriatrics and Gerontology - Director, Center for Gerontology and Social Science, Tokyo, Japan

Paul Aisen, MD Alzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego

Piu Chan, MD, PhD Professor and Director, Beijing Institute of Geriatrics, Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Disorders, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China

Kewei Chen, PhD Sr. Scientist and Sr. Biostatistician Director of Core Resources, Neuroimaging Research and Analysis Lab. Banner Alzheimer’s Institute, Banner Health Director, Data Management & Statistics Core (DMSC) The Arizona Alzheimer’s Disease Core Center (ADCC) National Alzheimer’s Coordinating Center (NACC) Research Professor, Dept. of Neurology, College of Medicine-Phoenix, Univ. of Arizona ; ASU School of Mathematics and Statistics ; Beijing Normal University; Med-X Institute, Shanghai Jiao Tong University
Liang-Kung Chen, MD, PhD  
Director, Center for Geriatrics and Gerontology, Taipei Veterans General Hospital Professor and Director, Aging and Health Research Center, National Yang Ming University President, Taiwan Association of Integrated Care, Taiwan

Jeffrey L. Cummings, M.D., Sc.D  
Camille and Larry Ruvo Chair for Brain Health Director, Cleveland Clinic Lou Ruvo Center for Brain Health Director, Center for Neurodegeneration and Translational Neuroscience Professor, Cleveland Clinic Lerner College of Medicine Las Vegas, Nevada – USA

Rachelle Doody, MD, PhD  
Global Head of Neurodegeneration, Roche, Basel, Switzerland

Lei Feng, MD  
Principal Investigator & Research Assistant Professor Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore - Singapore

Phyllis Barkman Ferrell  
AD Platform Vice President and Global Business Development Leader, Eli Lilly & Company, Indianapolis - USA

Meiyu Geng, MD, PhD  
Professor and Principal investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

Jianping Jia, MD, PhD  
Xuan Wu Hospital, Capital Medical University, Key Laboratory of Geriatric Cognitive Disorders, Center of Alzheimer’s Disease, Institute for Brain Disorders, Key Laboratory of Neurodegenerative Diseases, National Clinical Research Center for Geriatric Disorders, Beijing, China

Jun Li MD, PhD  
Department of Geriatrics, Center of Gerontology and Geriatrics, Department of Geriatrics, West China Hospital of Sichuan University, Chengdu, China

Reshma Merchant MD, PhD  
Head, Division of Geriatric Medicine, National University Hospital, Singapore

So Young Moon, MD, PhD  
Department of Neurology, School of Medicine, Ajou University, Suwon, South Korea

Ivana Rubino, MD  
Senior Medical Director, Alzheimer’s Disease Leader, Biogen, Boston MA - USA

Takashi Sakurai MD, PhD  
Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu City, Aichi Prefecture, Japan

Yong Shen, PhD  
Distinguished Professor of Neuroscience and Neurology Director Neurodegenerative Disorder Research Center, University of Science and Technology of China, Institute on Aging and Brain Disorders, University Al lied Hospital, University of Science and Technology of China, Member, Hefei Matrical Science National Laboratory at Microscale, Member, Excellent Center for Brain Sciences and Arti cial Intelligence in China Academy of Sciences, Heife, China

Jiong Shi MD, PhD, FAAN  
Professor, Department of Neurology, Barrow Neurological Institute, Phoenix, USA

Jacques Touchon, MD, PhD  
Montpellier School of Medecine INSERM U1061

Bruno Vellas, MD, PhD  
Chair of the Gerontopole & Department of Geriatric Internal Medicine at the Toulouse University Hospital Member of the INSERM UMR 1027, adjunct professor at the Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA, Chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training since September 2017

Ninie Wang  
CEO, Pinetree Care Group, Beijing, China

Jin-Tai Yu, MD, PhD  
Assistant President of Hospital Director, Clinical Research Center Vice Chairman, Department of Neurology, Professor of Neurology Qingdao Municipal Hospital, Qingdao University Qingdao, China

Jing Zhang, M.D., Ph.D.  
Professor of Pathology, Shaw Endowed Chair in Neuropathology, Adjunct Professor of Neurology, Ophthalmology and Oral Health Sciences, University of Washington School of Medicine - Seattle, WA

Zheng-Xin Zhang, M.D., Ph.D.  
Departments of Neurology, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, China Beijing Brain Health Center, Beijing, China

Kate Zhong, M.D., MSc, FRCP.  
CSO Global Alzheimer’s Platform Foundation Washington, DC - USA
Friday, OCTOBER 11

8.30 a.m  Opening Ceremony

9.00 a.m  ORAL COMMUNICATIONS

9.00 a.m  OC1 - Why do we need an Asian brain template in clinical trials of Alzheimer’s disease?
A comparative study of brain structures between Asian vs. Caucasian brains
Hyun Kook LIM (1), Dong Woo KANG (2), Sheng-Min WANG (3), Sung-Jin SON (4)
(1) Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, South Korea, (2) Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, (3) Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea – Seoul, South Korea, (4) NEUROPHET, Inc., Seoul, South Korea

9.15 a.m  OC2 - The Phase 2 study of BAN2401 in early Alzheimer’s disease demonstrated both a dose-dependent reduction in brain amyloid plaques and slowing progression of clinical symptoms
Takuya YAGI, Eisai Co., Ltd., Japan

9.30 a.m  OC3 - Continued large amyloid PET reductions at 36 months in the gantenerumab open-label extension studies
Gregory KLEIN (1), Paul DELMAR (2), Geoffrey A. KERCHNER (1), Carsten HOFMANN (1), Danielle ABI-SAAB (2), Smijana RISTIC (2), Sunita REHAL (1), Nicola VOYLE (3), Monika BAUDLER (2), Paulo FONTOURA (2), Rachelle DOODY (2)
(1) Roche Pharma Research Early Development, Basel, Switzerland, (2) Roche/Genentech Product Development, Neuroscience, Basel, Switzerland, (3) Roche Products Ltd, Welwyn Garden City, United Kingdom, (4) Genentech Inc., South San Francisco, USA

9.45 a.m  OC4 - Sodium oligomannate therapeutically harnesses gut bacterial amino acids-shaped neuron inflammation to inhibit Alzheimer’s disease progression
Meiyu GENG (1), Xinyi WANG (2), Guangqiang SUN (2), Teng FENG2, Jing ZHANG (2), Xun HUANG (1), Tao WANG (1) and Zuqun XIE (1)
(1) State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China, (2) Shanghai Green Valley Pharmaceutical Co. Ltd, Shanghai, China, (3) Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; Alzheimer’s Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai, China

10.00 a.m  Official photo of the CTAD Asia-China Meeting

10.05 a.m  Coffee Break and poster sessions

10.30 a.m  KEYNOTE 1
Progress for the CHINA INITIATIVE on NEURODEGENERATION in AGING
Piu Chan, MD, PhD - Professor and Director, Beijing Institute of Geriatrics, Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National Clinical Research Center for Geriatric Disorders, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China

11.00 a.m  SYMPOSIUM 1
Biomarker, AI imaging and clinical cohort development in China
PRESENTATION 1: China national clinical research center Alzheimer disease and Neurodegenerative Disorder Research (CANDOR study)
Jiong Shi, MD PhD FAAN, Department of Neurology Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Friday, OCTOBER 11

**PRESENTATION 2**: Bio fluid biomarkers in clinical phenotypes in Chinese patients
Yong Shen, MD, PhD, Neurodegenerative Disorder Research Center, University of Science and Technology of China, Institute on Aging and Brain Disorders, University Affiliated Hospital, University of Science and Technology of China, Hefei Material Science National Laboratory at Microscale, Excellent Center for Brain Sciences and Artificial Intelligence in China Academy of Sciences, Hefei, China

**PRESENTATION 3**: How to assess cognitive impairment using MRI
Yaou Liu, MD, PhD Director, Department of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

**PRESENTATION 4**: Cognitive impairment in adult patients with anti-N-methyl-D-aspartate receptor encephalitis
Benyan Luo, MD, PhD, Chief Physician and Section Director Department of Neurology, The first affiliated hospital of medical college of Zhejiang University, China

12.00 p.m Lunch

1.30 p.m **ORAL COMMUNICATIONS**

1.30 p.m **OC5** - Plasma biomarkers promisingly differentiate Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Huei-Ling LIU (1), Shieh-Yueh YANG (1), Ming-Jang CHIU (1), Chin-Hsien LIN (1), Wei-Che LIN (4), Fu-Chi YANG (5), Pai-Yi CHIU (6), W.P. CHEN (2)
(1) MagQu Co., Ltd., Taiwan, (2) MagQu LLC, USA, (3) National Taiwan University Hospital, Taiwan, (4) Kaohsiung Chang Gung Memorial Hospital, Taiwan, (5) Tri-Service General Hospital, Taiwan, (6) Show Chwan Memorial Hospital, Taiwan

1.45 p.m **OC6** - Inhibition of endocytic pathway of BACE1 as a therapeutic strategy for Alzheimer disease treatment
Beka SOLOMON - Tel Aviv university, Israel

2.00 p.m **OC7** - Correlation between amyloid reduction and clinical outcomes: exploratory analyses from the gantenerumab Scarlet RoAD and Marguerite RoAD open-label extension studies
Gregory KLEIN (1), Paul DELMAR (2), Geoffrey A. KERCHNER (2), Guoqiao WANG (3), Randall BATEMAN (3), Sunita REHAL (4), Nicola VOYLE (4), Mirjana ANDJELKOVIC (2), Danielle ABI-SAAB (2), Szo a BULLAIN (2), Smiljana RISTIC (2), Monika BAUDLER (2), Paulo FONTOURA (2), Rachelle DOODY (2)
(1) Roche/Genentech Product Development, Neuroscience, Basel, Switzerland, (2) Roche Pharma Research and Early Development, Basel, Switzerland, (3) Washington University, School of Medicine, USA, (4) Roche Products Development Ltd, Welwyn Garden City, UK, (5) Genentech Inc., South San Francisco, USA

2.15 p.m **OC8** - Longitudinal trajectories of Alzheimer’s ATN biomarkers in nondemented elderly adults
Jin-Tai YU (1), Meng-Shan TAN (1), Xi JI (1), Jie-Qiong LI (1), Qiang DONG (1), Chuan-Tao ZUO (1), Lan TAN (1), John SUCKLING (1)
(1) Huashan Hospital, Shanghai Medical College, Fudan University, China, (2) Qingdao Municipal Hospital, Qingdao University, China, (3) Dalian Medical University, China, (4) University of Cambridge, UK

2.30 p.m **KEYNOTE 2**
Dementia Situation and Clinical Trials in China
Jianping Jia, MD, PhD, Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China

3.00 p.m Coffee break and poster sessions
Friday, October 11

3.30 p.m SYMPOSIUM 2
How to design a clinical trial protocol in AD

PRESENTATION 1: What we have learned from past drug trials in AD, lessons for the future
Bruno Vellas, MD, PhD - Chair of the Gerontopole & Department of Geriatric Internal Medicine at the Toulouse University Hospital, Toulouse, France

PRESENTATION 2: Primary and secondary outcomes
Atsushi Iwata, M.D. Ph.D., Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

PRESENTATION 3: Use of biomarkers (CSF, blood, imaging)
Richard Batrla, MD, PhD, MBA, Roche Diagnostics International, Rotkreuz, Switzerland, Gregory Klein, PhD, F. Hoffmann-La Roche Ltd. Basel, Switzerland

4.30 p.m ORAL COMMUNICATIONS

4.30 p.m OC9 - Development of a ketogenic drug for Alzheimer’s disease
Judy Walker, Cerecin, Singapore

4.45 p.m OC10 - Characterization of MemTrax, a screening instrument for Alzheimer’s disease
Xianbo Zhou, M.D., Ph.D. - SJN Biomed LTD, Kunming, China; Center for Alzheimer’s Research, Washington Institute of Clinical Research, USA

Saturday, October 12

9.00 a.m ORAL COMMUNICATIONS

9.00 a.m OC11 - Collaborative Global-Local Network for Classification of Patients with Alzheimer’s Diseases and Cognitively Unimpaired Individuals: A Neurodegeneration Assessment Tool for Patient inclusion in AD trial
Kewei CHEN (1), Wuyang CHEN (1), Ye YUAN (1), Eric REIMAN (2), Xiaofen LIU (1), Frank LEE (4), Yaojing CHEN (3), Zhanjun ZHANG (3), Zhangyang WANG (1)
(1) Shanghai Green Valley Pharmaceutical, China, (2) Banner Alzheimer’s Institute, USA (3) State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, China, (4) Green Caddy LLC, USA

9.15 a.m OC12 - Endothelial BACE1-mediated cleavage of occludin contributes to cerebral small vessel pathology and neuronal dysfunction
Feng GAO, University of Science and Technology of China, China

9.30 a.m OC13 - Microtubule-associated protein 1B rescues memory decline in Alzheimer’s disease model mice
Fuyuki MITSUYAMA, Tenjyu Hospital, Japan

9.45 a.m OC14 - Cerebrovascular Disease and Alzheimer’s Disease
Yicheng ZHU, Department of Neurology, Peking Union Medical College Hospital, Beijing, China
Saturday, OCTOBER 12

10.00 a.m Coffee break and poster sessions

10.30 a.m KEYNOTE 3
Chinese National Clinical Research Center for Dementia Platform
Jiong Shi MD, PhD, FAAN - Professor, Department of Neurology, Barrow Neurological Institute, Phoenix, USA

11.00 a.m SYMPOSIUM 3
Biomarkers for detection of Alzheimer’s disease: the key to successful drug development and improved clinical practice

PRESENTATION 1: Current use and future potential of biomarker imaging in Alzheimer’s disease
Gregory Klein, PhD, F. Hoffmann-La Roche Ltd., Basel, Switzerland

PRESENTATION 2: Fluid biomarkers for detection of Alzheimer’s disease
Rich Batrla, MD, PhD, MBA, Roche Diagnostics International, Rotkreuz, Switzerland

PRESENTATION 3: Current use, availability and opportunities for Alzheimer’s disease biomarkers in China
Piu Chan, MD, PhD, Beijing Institute of Geriatrics, Xuanwu Hospital of Capital Medical University, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China

PRESENTATION 4: Alzheimer’s disease pipeline and commitment to China
Michele Landau, PhD, PharmD, F. Hoffmann-La Roche Ltd., Basel, Switzerland

12.00 p.m Lunch and poster sessions

1.00 p.m KEYNOTE 4
Beijing Aging Brain Rejuvenation Initiative: aging with grace
ZhanJun Zhang, State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing

1.30 p.m LATE BREAKING ORAL COMMUNICATIONS

1.30 p.m LB1 - Alzheimer’s disease and gut microbiota: a potential for prevention and treatment?
Jacques Touchon, MD, PhD, (4,5), Laura Auboyer, PhD (1), Johann Meunier, PhD (2), Laura Ceolin, PhD (2), François J. Roman, PhD (2), Rémy Burcelin, PhD (3), Guillaume Blivet, MS (1)
(1) REGEnLIFE SAS, Montpellier, France, (2) Amylgen SAS, Montferrier-sur-Lez, France, (3) Vaiomer SAS, Labège, France, (4) INSERM U1061, Montpellier, France, (5) University of Montpellier, France

1.45 p.m LB2 - Is cognitive impairment associated with cerebral microbleeds in systemic immunoglobulin light chain amyloidosis?
Yong SHEN (1,2), Qiong WANG (1,2), Xinyi LV (1), Yuhua CHEN (1)
(1) Institute on Aging and Brain Disorders and Department of Neurology, University Af liated Hospital, University of Science and Technology of China, China, (2) Neurodegenerative Disorder Research Centre (NDRC), University of Science and Technology of China, China

2.00 p.m LB3 - Clinical applications of APN-1607 tau PET imaging in neurodegenerative tauopathies
Ming-Kuei JANG (1,2,3), Poe-Jou CHEN (1), Kun-Ju LIN (4), Chin-Chang HUANG (4), Ing-Tsung HSIAO (4), Qing-Fang YANG (4), Maiko ONO (5), Hitoshi SHIMADA (5), Naruhioko SAHARA (5), Ming-Rong ZHANG (5), Makoto HIGUCHI (5), Yi-Hui GUAN (6), Chuan-Tao ZUO (6), Jian WANG (6), Qianhua ZHAO (6)
(1) APRINOIA Therapeutics, Taiwan, republique de chine, (2) APRINOIA Therapeutics, China, (3) APRINOIA Therapeutics, Japon, (4) ChaGung Memorial Hospital and Chang Gung University, Taiwan, republique de chine, (5) National Institute for Quantum and Radiological Science and Technology (QST), Japon, (6) Huashan Hospital, Chine
Saturday, OCTOBER 12

2.15 p.m  **LB4** - Plasma biomarkers and neurodegeneration of Alzheimer’s disease: report of ten cases.  
Haiqun XIE, Department of Neurology, Affiliated Foshan Hospital of Sun Yat-sen University, China

2.30 p.m  **LB5** - Comparison of diagnostic efficiencies by using PERSI (white matter) and whole cerebellum as reference region in 18F-APN-1607 in Alzheimer’s disease  
Weiqi BAO (1), Jiaying LU (1), Huwei ZHANG (1), Ling LI (1), Ming LI (1), Min WANG (2), Jiehui JIANG (2), Yihui GUAN (1), Chuantao ZUO (1)  
(1)PET Center, Huashan Hospital, Fudan University, China, (2)Shanghai Institute for Advanced Communication and Data Science, Shanghai University, China

2.45 p.m  **LB6** - Whole Brain Mapping of Dysregulated Metabolic Pathways in Alzheimer’s Disease  
Xiao Li YANG, Xiao Qun WANG, Feng GAO, Guang Ming HUANG, Yong SHEN  
University of Science and Technology of China, China

3.00 p.m  **KEYNOTE 5**  
AD clinical trials and related activities in Japan  
Takeshi Iwatsubo, MD, PhD - Professor of Neuropathology at the School of Medicine, University of Tokyo, Tokyo, Japan

3.30 p.m  Coffee break and poster sessions

4.00 p.m  **Closing Ceremony**
**POSTERS**

### Theme: CLINICAL TRIALS: METHODOLOGY

**P1**
Effectiveness of interventions on depression of informal caregivers of people with dementia in China: A systematic review  
Jianing QI, Shuying ZHANG - (1) Tongji University, China

### Theme: CLINICAL TRIALS: IMAGING

**P2**
Aprinoia Therapeutics’s tau small molecule discovery platform: proof of target engagement in both cellular and in vivo models  
Paul TEMPEST (1), Yih-Shyan LIN (1), Chin-Yin TAI (1), Meng-Fang WU (1), Kun-Ju LIN (2), Ing-Tsung HSIAO (3), Ming-Kuei JANG (1) - (1) Aprinoia, Taiwan, (2) Chang Gung Memorial Hospital, Taiwan, (3) Chang Gung University, Taiwan

**P3**
Preliminary study of 18F-APN-1607 PET imaging on tau tangles in the brain of Alzheimer’s disease   
Jiaying LU (1), Yihui GUAN (1), Qianhua ZHAO (2), Ming LI (1), Axel ROMINGER (3), Kuangyu SHI (3), Chuantaoh ZUO (1) - (1) PE PET center, Huashan Hospital, Fudan University, China, (2) Department of Neurology, Huashan Hospital, Fudan University, China, (3) Department of Nuclear Medicine, Universität Bern, Switzerland

**P4**
Feeling Worse Memory Accelerated the Patterns of Alzheimer’s Atrophy  
Ziqi WANG - (1) Department of Neurology, Chengdu Fifth People’s Hospital, China

### Theme: CLINICAL TRIALS: BIOMARKERS INCLUDING PLASMA

**P5**
The novel Aβ aggregation modulators GAL-101 and GAL-201 reverse the synaptotoxic effects of Aβ oligomers and thereby show therapeutic potential in Alzheimer’s disease   
Christopher PARSONS (1), Gerhard RAMMES (2), Hermann RUSS (1), Andy PEARLMAN (1) - (1) Galimedix Therapeutics, inc, United States, (2) Die Technische Universität München, Germany

**P6**
Gut microbiota interacts with intrinsic brain activity of patients with amnestic mild cognitive impairment  
Guoping PENG (1), Ping LIU (1), Baohong WANG (2) - (1) Department of Neurology, First Affiliated Hospital, Zhejiang University College of Medicine, China, (2) State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University, China

**P7**
Plasma neurofilament light chain (NfL) discriminates not only AD but also PD from normal controls  
Shieh-Yueh YANG (1, 2), Huei-Chun LIU (1), Ming-Jang CHIU (3), Chin-Hsien LIN (3) - (1) MagQu Co., Ltd., Taiwan (2) MagQu LLC, United States, (3) National Taiwan University Hospital, Taiwan

**P8**
Plasma pyroglutamated amyloid beta 3-40 as a promising biomarker for amyloid pathology  
Huei-Chun LIU (1), Pei-Ning WANG (2), Kun-Ju LIN (3), Kaj BLENNOW (4, 5), Henrik ZETTERBERG (6, 5, 7), Shieh-Yueh YANG (1, 8) - (1) MagQu Co., Ltd., Taiwan (2) Taipei Veterans General Hospital, Taiwan (3) Linkou Chang Gung Memorial Hospital, Taiwan (4) University of Gothenburg - Mölndal (Sweden), Sweden, (5) Sahlgrenska University Hospital, Sweden, (6) University of Gothenburg, Sweden, (7) UCL Queen Square Institute of Neurology, United Kingdom, (8) MagQu LLC, United States

**P9**
Plasma TDP-43 discriminates frontotemporal dementia from Alzheimer’s disease and Parkinson’s disease  
Huei-Chun LIU (1), Shieh-Yueh YANG (1, 2), Chia-Shin HO (1), Hsin-Hsien CHEN (1), Wen-Ping CHEN (2), Chin-Hsien LIN (3), Ming-Jang CHIU (3) - (1) MagQu Co., Ltd., Taiwan (2) MagQu LLC, United States, (3) National Taiwan University Hospital, Taiwan

**P10**
Concordence in measured plasma biomarkers of dementia between cases of using EDTA K2 and EDTA K3 tubes  
Huei-Chun LIU (1), Shieh-Yueh YANG (1, 2), W.P. CHEN (2) - (1) MagQu Co., Ltd., Taiwan (2) MagQu LLC, United States
**POSTERS**

**Theme: CLINICAL TRIALS: BIOMARKERS INCLUDING PLASMA (suite)**

**P11** Significant correlation between Abeta1-42 and p-Tau181 in plasma in AD patients, but not in PD or FTD patients  
Shieh-Yueh YANG (1, 2), Ming-Jang CHIU (3), Ta-Fu CHEN (3), Chin-Hsien LI (3), Fu-Chi YANG (4), Kaj BLENNOW (5, 6) - (1) MagQu Co., Ltd., Taiwan, (2) MagQu LLC, United States, (3) National Taiwan University Hospital, Taiwan, (4) Tri-Service General Hospital, Taiwan, (5) University of Gothenburg, Sweden, (6) Sahlgrenska University Hospital, Sweden

**P12** Plasma amyloid beta 1-42 and Tau Protein predict the cognitive decline in aMCI patients  
Shieh-Yueh YANG (1, 2), Pei-Ning WANG (3), Chaur-Jong HU (4) - (1) MagQu Co., Ltd., Taiwan, Republic of china, (2) MagQu LLC, United States, (3) Taipei Veterans General Hospital, Taiwan, (4) Taipei Medical University Hospital-Shuang Ho Hospital, Taiwan

**P13** A novel method RT-QuIC based on high sensitivity material for detection of misfolded Aβ oligomers in Alzheimer’s Disease  
Shu YU (1), Yueping LIU (2) - (1) the third affiliated hospital of air force military medical university, China, (2) 911st hospital of joint logistic troop, PLA, China

**P14** Comparison of cerebrospinal fluid biomarkers of Alzheimer’s disease with commercial kits  
Ho-Won LEE, Pan Woo KO, Kyunghun KANG - (1) Kyungpook National University Chilcok Hospital, South Korea

**P15** Prevalence and longitudinal clinical outcomes of Alzheimer’s ATN biomarker profiles: a longitudinal study  
Jin-Tai YU (1), Jie-Qiong LI (2), John SUCKLING (3), Lei FENG (4), Yan-Jiang WANG (5), Qiang DONG (1), Lan TAN (2), Vincent MOK (6), Paul S AISEN (7), Weiner MICHAEL (8) - (1) Huashan Hospital, Shanghai Medical College, Fudan University, China, (2) Qingdao Municipal Hospital, Qingdao University, China, (3) University of Cambridge, United Kingdom, (4) Yong Loo Lin School of Medicine, National University of Singapore, Singapore, (5) Daping Hospital, Third Military Medical University, China, (6) Faculty of Medicine, The Chinese University of Hong Kong, China, (7) Alzheimer’s Therapeutic Research Institute, University of Southern California, United States, (8) University of California, San Francisco, United States

**Theme: COGNITIVE ASSESSMENT AND CLINICAL TRIALS**

**P16** Visualization and quantification of spatial pattern of FDG-PET measured hypometabolism in individual patients: Assisting clinical diagnosis of Alzheimer’s disease in clinical trials  
Kewei CHEN (1, 2, 3), Qiu HUANG (1), Xiaofen LIU (1), Xiaolin GE (1), Frank LEE (4), Team PHOENIX (1), Yaojing CHEN (3), Eric REIMAN (2), Zhanjun ZHANG (3), Meiyu GENG (1) - (1) Shanghai Green Valley Pharmaceutical, China, (2) Banner Alzheimer’s Institute, United States, (3) State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, China, (4) Green Caddy LLC, United States

**P17** Impact of smoking on visuospatial function, lipid profile and small-world property in a non-dementia aging male Chinese population  
Xia LI, Jiayuan QIU - (1) Shanghai Jiaotong University School of Medicine Affiliated Mental Health Centre, China

**Theme: BEHAVIORAL DISORDERS AND CLINICAL TRIALS**

**P18** Efficacy of intergenerational learning programs for elders with mild cognitive impairment  
Yuan-Ju LIAO - (1) National Yang-Ming University, Taiwan, Republic of china
POSTERS

Theme: ANIMAL MODEL AND CLINICAL TRIAL

P19  BACE1 regulates gabaa ß receptors expression in AD pathology
Gao FENG, Bao HONG, Yang XIAOLI, Shen YONG - (1) USTC, China

P20  CogniXtra preventive treatment affords neuroprotection against amyloid beta 25-35 peptide-induced toxicity in mice
Francois J. ROMAN (1), Johann MEUNIER (1), Jacques TOUCHON (2), Laura CEOLIN (1), Jean-Marie BUTTERLIN (3), Guillaume BLIVET (4) - (1) Amylgen, France, (2) INSERM U1061, Montpellier University Hospital, France, (3) HOD, Netherlands, (4) Liberal professional, France

P21  Tau immunotherapy for Alzheimer's Disease targeting synaptically accumulated tau species
Chin-Yin TAI, Haou-Tzong MA, Shien-Chien HUANG, Chung-Lin LI, Meng-Fang WU, Chia-Lin WU, Shih-Han LIN, Ming-Kuei JANG - (1) APRINOIA Therapeutics Inc., Taiwan

Theme: NEW THERAPIES AND CLINICAL TRIALS

P22  Promising anti-AD dimers: from relieving symptoms to modifying disease through multiple targets
Yifan HAN, Shengquan HU, Shinghung MAK, Jiajun WANG - (1) The Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hong Kong

P23  Neuroprotective effect of a new photobiomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support a novel hypothesis for therapeutic approach of Alzheimer’s disease
Jacques TOUCHON (1, 2), Guillaume BLIVET (3), Laura AUBOYER (3), Johann MEUNIER (4), François J. ROMAN (4) - (1) INSERM U1061, France, (2) University of Montpellier, France, (3) REGEnLIFE SAS, France, (4) Amylgen SAS, France

P24  GRADUATE I and II better by design or how to optimize study designs by integrating learnings from previous studies
Jiong SHI (1, 2), Nathalie PROSS (3), Smiljana RISTIC (3), Mirjana ANDJELKOVIC (3), Danielle ABI-SAAB (3), Szo a BULLAIN (3), Beijue SHI (3), Paul DELMAR (3), Carsten HOFMANN (4), Alison SEARLE (5), Monika BAUDLER (3), Paulo FONTOURA (3), Rachelle DOODY (3, 6) - (1) National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, China, (2) Barrow Neurological Institute, Dignity Health St. Joseph’s Hospital and Medical Center, USA, (3) F. Hoffmann-La Roche Ltd., Product Development Neuroscience, Switzerland, (4) F. Hoffmann-La Roche Ltd., Roche Pharma Research and Early Development, Switzerland, (5) Roche Products Ltd., Operations, UK, (6) Product Development Neuroscience, Genentech, Inc., Switzerland

Theme: CLINICAL TRIAL RESEARCH FACILITIES

P25  Non-cognitive symptoms increasing caregiver’s burden of Alzheimer’s disease
Li LIN (1), Xu JUN (2) - (1) Department of Neurology, Dongyang people’s hospital, China, (2) Department of Cognitive Neurology, China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing Tian Tan Hospital, Affiliated to Capital Medical University, China
CONGRESS VENUE
The Hilton Beijing

Hilton Beijing
1 Dong Fang Rd
North Dongsanhuan Rd
Beijing, 100027
CHINA

Book your room on our website
www.ctad-asia.com

Follow us on WeChat

Book your room on our website
www.ctad-asia.com